Continuous subcutaneous apomorphine infusion in Parkinson’s disease: causes of discontinuation and subsequent treatment strategies.

Continuous subcutaneous apomorphine infusion in Parkinson’s disease: causes of discontinuation and subsequent treatment strategies.
Related ArticlesContinuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies. Neurol Sci. 2019 May 20;: Authors: Olivola E, Fasano A, Varanese S, Lena F, Santilli M, Femiano C, Centonze D, Modugno N Abstract Continuous subcutaneous apomorphine infusion (CSAI) is a well-recognized therapeutic option for the management of motor fluctuations in Parkinson's disease (PD), although clinical ... read more
Source: PubMedPublished on 2019-05-22